Adaptive Biotechnologies COO Julie Rubinstein Sells $919,870 in Stock

Adaptive Biotechnologies President and COO Julie Rubinstein sold $919,870 of common stock between October 9 and October 13, 2026. The transaction followed the exercise of fully vested stock options and was conducted under a pre-established trading plan.

Prior to the sales, Rubinstein acquired 35,643 shares through the exercise of stock options at a strike price of $12.14 per share. The subsequent disposal of these shares was executed pursuant to a Rule 10b5-1 trading plan, which the executive adopted on November 18, 2025.

Understanding Rule 10b5-1 Trading Plans

Rule 10b5-1 plans are a common mechanism used by corporate insiders to manage equity holdings while maintaining regulatory compliance. These plans allow executives to establish a predetermined schedule for selling shares at future dates or price points.

By setting these parameters in advance, insiders can demonstrate that their trades were not motivated by material non-public information. This structure provides a defense against potential allegations of insider trading, as the decisions regarding the timing and volume of sales are made before the insider has access to specific, confidential company developments.

Insider Equity Management

For executives at biotechnology firms, option exercises and subsequent sales are frequently tied to compensation packages that vest over multi-year periods. In this instance, the acquisition of shares at the $12.14 exercise price and their subsequent sale under the 10b5-1 plan reflect a standard approach to liquidity management for company leadership.

Adaptive Biotechnologies, which focuses on immune-medicine and diagnostic testing, utilizes such equity-based compensation to align the interests of its executive team with corporate performance. The adoption of the trading plan nearly a year prior to the October 2026 sales indicates that the transaction was part of a financial strategy rather than a reactive move to immediate market conditions.